Medsite's E-Pharma Marketing Gain Share Methodology Increases WellSpring Pharmaceutical Corporation's Dyrenium Prescriptions; Medsite Pharmaceutical Services Offers A Zero Cost, Zero Risk Option For Mature Therapies With Limited Marketing Resources
10/19/2005 5:12:26 PM
Medsite Pharmaceutical Services LLC, a new division of Medsite, today announced the results from its initial pilot gain share program with the WellSpring Pharmaceutical Corporation. After six months of Phase I promotion for Dyrenium100mg(R), a 40-year-old diuretic therapy, a target group, representing 15 percent of Dyrenium prescribing physicians, generated a 40 percent increase in new prescriptions written. These results were established by a promotional evaluation study conducted by IMS Management Consulting Services.
comments powered by